Human Immune Response to Immunization with a Structurally Defined Polypeptide Fragment of Streptococcal M Protein
Overview
General Medicine
Affiliations
We tested the ability of pepsin-extracted, highly purified M protein to induce type-specific immunity in experimental animals and humans. M protein was prepared from limited peptic digests of whole group A type 24 streptococci and was purified to chemical homogeneity as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, quantitative amino acid analysis, and Edman degradation. For vaccination, the lyophilized M24 protein preparation (pep M24) was precipitated in aluminum hydroxide. When injected into laboratory animals, alum-precipitated pep M24 produced type-specific protective antibodies and was free of non-type-specific immunoreactivity. In man, skin tests with 1-microgram doses of pep M24 were negative in all 37 adults tested. 12 adult human volunteers received two-four subcutaneous injections of 100-200 micrograms of alum-precipitated pep M24 at intervals of at least 2 wk. The immune response to pep M24 was measured by a variety of assays designed to detect (a) type-specific humoral antibodies (opsonophagocytic, long chain, and mouse protection tests); (b) total humoral antibodies (complement fixation and enzyme-linked immunosorbent assay); (c) cellular immunity (skin tests); and (d) heart cross-reactive antibodies (immunofluorescence). Type-specific opsonic antibodies developed in 10 of the 12 vaccinees, and positive delayed-type skin tests developed in 11. Immune sera from two of the vaccinees were effective in mouse-protection tests against challenge with M24 but not M6 streptococci. None of the volunteers developed heart-reactive antibodies or antibodies to non-type-specific M protein antigens. Alum-precipitated pep M24 was well-tolerated in man, and no serious local or systemic reactions were observed. Thus, pep M24 induces type-specific, protective antibodies in doses that are well-tolerated in man.
Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines.
Iyer V, Sagar V, Toor D, Lyngdoh V, Nongrum G, Kapoor M Cureus. 2023; 14(12):e33146.
PMID: 36721580 PMC: 9884514. DOI: 10.7759/cureus.33146.
Correlates of immunity to Group A Streptococcus: a pathway to vaccine development.
Frost H, Excler J, Sriskandan S, Fulurija A NPJ Vaccines. 2023; 8(1):1.
PMID: 36650164 PMC: 9844947. DOI: 10.1038/s41541-022-00593-8.
Spencer J, Penfound T, Salehi S, Aranha M, Wade L, Agarwal R Vaccine. 2021; 39(12):1773-1779.
PMID: 33642159 PMC: 8045747. DOI: 10.1016/j.vaccine.2021.01.075.
Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis.
Fischetti V Microbiol Spectr. 2019; 7(3).
PMID: 31111819 PMC: 11026073. DOI: 10.1128/microbiolspec.GPP3-0010-2018.
Bronze M, Dale J Am J Med Sci. 2010; 340(3):218-25.
PMID: 20697258 PMC: 2935929. DOI: 10.1097/MAJ.0b013e3181e939ab.